paraffin-embedded colorectal tissue microarray (tma (Indivumed gmbh)
Structured Review

Paraffin Embedded Colorectal Tissue Microarray (Tma, supplied by Indivumed gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/paraffin+embedded+tissue+microarray+sections/pmc06522288-179-22-26?v=Indivumed+gmbh
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers"
Article Title: Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
doi: 10.1158/1078-0432.CCR-18-2523
Figure Legend Snippet: (A) Baseline expression of selected DDR markers was demonstrated and quantified in a colorectal tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue microarray cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Techniques Used: Expressing, Microarray, Marker, Quantitation Assay, Derivative Assay
Figure Legend Snippet: Representative H&E and immunofluorescence (IFA) images from 3 patients with advanced colorectal cancer enrolled in NCI trial NCT01851369 before and 5 days after start of treatment with a DNA damaging therapeutic regimen consisting of TCR102 plus temozolomide administered orally once daily. Red scale bar represents 10 μm.
Techniques Used: Immunofluorescence

